NCT06044662 Prognostic Value of Biomarkers in Polyneuropathy.
| NCT ID | NCT06044662 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Rigshospitalet, Denmark |
| Condition | Polyneuropathies |
| Study Type | OBSERVATIONAL |
| Enrollment | 200 participants |
| Start Date | 2023-10-27 |
| Primary Completion | 2025-10 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 200 participants in total. It began in 2023-10-27 with a primary completion date of 2025-10.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Biomarkers for prognosis of patients with polyneuropathy.
Eligibility Criteria
Inclusion Criteria: * Minimum 18 years old. * Diagnosed with polyneuropathy, confirmed by nerve conduction study. * Can read and understand Danish. Exclusion Criteria: * Inability to perform physical tests due to comorbidity not associated to the patient's polyneuropathy.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06044662 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Polyneuropathies. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06044662 currently recruiting?
Yes, NCT06044662 is actively recruiting participants. Contact the research team at Tina.dysgaard@regionh.dk for enrollment information.
Where is the NCT06044662 trial being conducted?
This trial is being conducted at Copenhagen, Denmark.
Who is sponsoring the NCT06044662 clinical trial?
NCT06044662 is sponsored by Rigshospitalet, Denmark. The trial plans to enroll 200 participants.